Text

Toksisiti Hamatology Akibat Kemoterapi pada Penderita Kanker Paru Jenis Karsinoma Bukan Sel Kecil

---

Chemotherapy result at lung cancer patient be minimized by hematology imbalance during therarapy period. Present data show that grade 3 or 4 of hematology toxicities due to chemotherapy with regimen carboplatin + paclitaxel were rare. A cross sectional study have done to evaluhemotherapy weekly the hematology toxicities of carboplatin plus etoposide or paclitaxel as first line therapy in patients with advanced non small cell lung cancer (NSCLC). Thirty one patient with stage IIIB/IV NSCLC a performance status of 0-1 and no prior chemotherapy exposure were eligible. Patients received Carboplatin AUC-5 + etoposide 100mg/m2 or carboplatin AUC-5+ paclitaxel 175 mg/m2 at 3 weekly cycle. Leucocyte, hemoglobin and thrombocyte were count before and every week in during 2 cycle chemotherapy. A median of chemotherapy was 4 cyccle s(range 2-6) . Twenty five of 31 (80.6%) patients had anemia 18 of 31 (58,1%) had leucopenia, 3 of 31 (9.7%) had thrombocytopenia and 25 of 1 (80,6%) had neutropenia. Mostly hematology toxicities were mild. The most common toxicity was founded at week 2 in first cycle of chemotherapy. Grade ¾ hematology toxicities were seen include anemia 3 patients (10%), leucopenia 4 patients (12,8%), thrombocytopenia 0(0%) and Neutropenia 10 patients (40%). These results demonstrate that this regimen is an active and tolerable treatment for patients with advanced NSCLC.

---

Availability

Detail Information

Series Title

-

Call Number

Jurnal Respirologi Indonesia, 28(4):184-189

Publisher

Jakarta : Perhimpunan Dokter Paru Indonesia., 2008

Collation

6p.

Language

ISBN/ISSN

0853-7704

Classification

-

Content Type

-

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

drug therapy
lung neoplasms
HEMATOLOGY

Specific Detail Info

-

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment